{"id":539061,"date":"2021-09-16T08:04:01","date_gmt":"2021-09-16T12:04:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/"},"modified":"2021-09-16T08:04:01","modified_gmt":"2021-09-16T12:04:01","slug":"larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/","title":{"rendered":"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event"},"content":{"rendered":"
\n

BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that company management will participate in 1×1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event. The event is taking place virtually September 22-23, 2021.<\/p>\n

\n About\u00a0Larimar Therapeutics<\/strong>\n <\/p>\n

Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the\u00a0U.S.\u00a0as a potential treatment for Friedreich’s ataxia.\u00a0Larimar\u00a0also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit:\u00a0https:\/\/larimartx.com<\/a>.<\/p>\n

\n Investor Contact:<\/strong>
\n
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com<\/a>
(212) 915-2569<\/p>\n

\n Company Contact:<\/strong>
\n
Michael Celano
Chief Financial Officer
mcelano@larimartx.com<\/a>
(484) 414-2715<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that company management will participate in 1×1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event. The event is taking place virtually September 22-23, 2021. About\u00a0Larimar Therapeutics Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the\u00a0U.S.\u00a0as a potential treatment for Friedreich’s ataxia.\u00a0Larimar\u00a0also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by … <\/p>\n

Continue reading “Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-539061","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLarimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that company management will participate in 1×1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event. The event is taking place virtually September 22-23, 2021. About\u00a0Larimar Therapeutics Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the\u00a0U.S.\u00a0as a potential treatment for Friedreich’s ataxia.\u00a0Larimar\u00a0also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by … Continue reading "Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-16T12:04:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event\",\"datePublished\":\"2021-09-16T12:04:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/\"},\"wordCount\":173,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/\",\"name\":\"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ==\",\"datePublished\":\"2021-09-16T12:04:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/","og_locale":"en_US","og_type":"article","og_title":"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event - Market Newsdesk","og_description":"BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (\u201cLarimar\u201d) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,\u00a0today announced that company management will participate in 1×1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event. The event is taking place virtually September 22-23, 2021. About\u00a0Larimar Therapeutics Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the\u00a0U.S.\u00a0as a potential treatment for Friedreich’s ataxia.\u00a0Larimar\u00a0also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by … Continue reading \"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-16T12:04:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event","datePublished":"2021-09-16T12:04:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/"},"wordCount":173,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/","name":"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ==","datePublished":"2021-09-16T12:04:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNTExOSM0NDAzMTE1IzUwMDA3Nzg4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=539061"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539061\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=539061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=539061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=539061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}